Aclarion, Inc.ACONEarnings & Financial Report
Aclarion, Inc. is a medical technology company focused on developing non-invasive solutions for chronic lower back pain diagnosis and treatment. Its core offerings leverage proprietary magnetic resonance spectroscopy technology to accurately identify painful intervertebral discs, serving healthcare providers and patients across the United States, with key focus on the chronic pain management and spinal care segments.
Revenue
$18.9K
Gross Profit
$4.4K
Operating Profit
$-1.8M
Net Profit
$-1.7M
Gross Margin
23.2%
Operating Margin
-9666.2%
Net Margin
-9008.0%
YoY Growth
31.5%
EPS
$-2.93
Aclarion, Inc. Q3 FY2025 Financial Summary
Aclarion, Inc. reported revenue of $18.9K (up 31.5% YoY) for Q3 FY2025, with a net profit of $-1.7M (down 24.9% YoY) (-9008.0% margin). Cost of goods sold was $14.6K, operating expenses totaled $1.8M.
Key Financial Metrics
| Total Revenue | $18.9K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | 23.2% |
| Operating Margin | -9666.2% |
| Report Period | Q3 FY2025 |
Aclarion, Inc. Annual Revenue by Year
Aclarion, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $75.7K).
| Year | Annual Revenue |
|---|---|
| 2025 | $75.7K |
| 2024 | $45.7K |
| 2023 | $75.4K |
| 2022 | $60.4K |
Aclarion, Inc. Quarterly Revenue & Net Profit History
Aclarion, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $18.5K | +80.6% | $-1.9M | -10223.7% |
| Q3 FY2025 | $18.9K | +31.5% | $-1.7M | -9008.0% |
| Q2 FY2025 | $19.3K | +76.1% | $-1.6M | -8285.9% |
| Q1 FY2025 | $19.0K | +87.8% | $-2.0M | -10728.4% |
| Q4 FY2024 | $10.2K | -25.8% | $-2.0M | -19444.6% |
| Q3 FY2024 | $14.4K | -24.4% | $-1.4M | -9482.7% |
| Q2 FY2024 | $11.0K | -35.7% | $-1.2M | -11285.0% |
| Q1 FY2024 | $10.1K | -60.3% | $-2.4M | -23720.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10114 | $10971 | $14407 | $10232 | $18991 | $19319 | $18942 | $18478 |
| YoY Growth | -60.3% | -35.7% | -24.4% | -25.8% | 87.8% | 76.1% | 31.5% | 80.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.7M | $3.1M | $3.2M | $2.1M | $16.5M | $14.8M | $13.2M | $13.7M |
| Liabilities | $1.2M | $1.4M | $678267 | $1.2M | $699032 | $564422 | $699747 | $837287 |
| Equity | $2.5M | $1.6M | $2.5M | $970057 | $15.8M | $14.2M | $12.5M | $12.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.2M | $-1.1M | $-1.1M | $-922862 | $-2.5M | $-1.9M | $-1.2M | $-1.6M |